Adult acute lymphocytic leukemia. Future research directions.
This article reviews future research of potential benefit to adults with acute lymphocytic leukemia (ALL). This new research includes dose intensive anthracyclines, novel agents, STI571 for Philadelphia chromosome-positive ALL, and risk-oriented strategies.
Kantarjian
H M
HM
Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. hkantarj@mdanderson.org
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000145:classification / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015195:Drug Design; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy; D017053:Infection Control; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D012074:Remission Induction; D000069283:Rituximab; D015398:Signal Transduction / Q000187:drug effects
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab